1
|
Sarin R, Somsekhar SP, Kumar R, Pawan G, Sumeet J, Pramoj J, Vaishali Z, Firoz P, Parikh PM, Aggarwal S, Koul R. Practical consensus recommendations for tumor margins and breast conservative surgery. South Asian J Cancer 2020; 7:72-78. [PMID: 29721467 PMCID: PMC5909299 DOI: 10.4103/sajc.sajc_105_18] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
My suggestion: There is no difference in survival of breast cancer patients treated with either mastectomy or with breast conservation therapy combined with external beam radiotherapy. A positive margin (s) is an important factor contributing to the increased risk of local recurrence. However, in published literature, there is a lack of consensus on the definition of acceptable margin (s). As a result decision process about need for re-excision after positive margins remains uncrear.
Collapse
Affiliation(s)
- R Sarin
- Department of Surgical Oncology, Apollo Indraprastha Hospital, New Delhi, India
| | - S P Somsekhar
- Department of Surgical Oncology, Manipal Hospital, Bengaluru, Karnataka, India
| | - R Kumar
- Department of Surgical Oncology, Rajiv Gandhi Cancer Hospital, New Delhi, India
| | - Gupta Pawan
- Department of Surgical Oncology, Jaypee Hospital, Noida, Uttar Pradesh, India
| | - Jain Sumeet
- Department of Surgical Oncology, Fortis Hospital, Mohali, Punjab, India
| | - Jindal Pramoj
- Department of Surgery, Sir Ganga Ram Hospital, New Delhi, India
| | - Zamre Vaishali
- Department of Surgical Oncology, Max Hospital, New Delhi, India
| | - Pasha Firoz
- Department of Surgical Oncology, Apollo Indraprastha Hospital, New Delhi, India
| | - P M Parikh
- Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra, India
| | - S Aggarwal
- Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
| | - R Koul
- Department of Surgical Oncology, Sir Ganga Ram Hospital, New Delhi, India
| |
Collapse
|
2
|
Basade M, Singhal M, Rathi AK, Nandi M, Minhas S, Goswami C, Shinde S, Parikh PM, Aggarwal S. Practical consensus recommendations regarding the management of HER2 neu positive metastatic breast cancer. South Asian J Cancer 2020; 7:146-150. [PMID: 29721483 PMCID: PMC5909294 DOI: 10.4103/sajc.sajc_123_18] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
Metastatic breast cancer (MBC) is cancer that has spread from the breast to another part of the body or has come back in another distant location. Treatment options for MBC depend on several factors, including where the cancer has spread, the patient's overall health, and the levels of hormone receptors and HER2 in the tumour. Over-expression of HER2 is generally considered to be a negative prognostic feature because it accompanies an increase in breast cancer mortality. However, the development of agents that specifically target HER2 has improved the management of patients with these tumours.[7],[8],[9],[10] This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations in regards with the use of these agents and the management of HER2 positive MBC for the benefit of community oncologists.
Collapse
Affiliation(s)
- M Basade
- Department of Medical Oncology, Saifee Hospital, Mumbai, Maharashtra, India
| | - M Singhal
- Department of Medical Oncology, Indraprastha Apollo Hospital, New Delhi, India
| | - A K Rathi
- Department of Radiation Oncology, MAMC, New Delhi, India
| | - M Nandi
- Department of Medical Oncology, Jaypee Hospital, Noida, Uttar Pradesh, India
| | - S Minhas
- Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
| | - C Goswami
- Department of Medical Oncology, Jaypee Hospital, Noida, Uttar Pradesh, India
| | - S Shinde
- Department of Radiation Oncology, Medica Superspecialty Hospital, Kolkata, West Bengal, India
| | - P M Parikh
- Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra, India
| | - S Aggarwal
- Department of Radiation Oncology, Medica Superspecialty Hospital, Kolkata, West Bengal, India
| |
Collapse
|
3
|
Bajpai J, Majumdar A, Satwik R, Rohatgi N, Jain V, Gupta D, Agarwal R, Mittal S, Verma SK, Parikh PM, Aggarwal S. Practical consensus recommendations on fertility preservation in patients with breast cancer. South Asian J Cancer 2020; 7:110-114. [PMID: 29721475 PMCID: PMC5909286 DOI: 10.4103/sajc.sajc_113_18] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Young women diagnosed with cancer today have a greater chance of long-term survival than ever before. Successful survivorship for this group of patients includes maintaining a high quality of life after a cancer diagnosis and treatment; however, lifesaving treatments such as chemotherapy, radiation, and surgery can impact survivors by impairing reproductive and endocrine health. Expert oncologists along with reproductive medicine specialists discuss fertility preservation options in this chapter since fertility preservation is becoming a priority for young women with breast cancer. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations for the benefit of community oncologists.
Collapse
Affiliation(s)
- Jyoti Bajpai
- Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| | - A Majumdar
- Center of IVF and Human Reproduction, Sir Gangaram Hospital, New Delhi, India
| | - R Satwik
- Center of IVF and Human Reproduction, Sir Gangaram Hospital, New Delhi, India
| | - N Rohatgi
- Department of Medical Oncology, Max Saket Hospital, New Delhi, India
| | - V Jain
- Department of Gynaecology and Obstretics, Ludhiana Medicity Hospital, Ludhiana, Punjab, India
| | - D Gupta
- Department of Medical Oncology, Dharamshila Cancer Hospital, New Delhi, India
| | - R Agarwal
- Department of Surgical Oncology, Medanta Hospital, Gurugram, Haryana, India
| | - S Mittal
- Department of Medical Oncology, Action Balajee Cancer Center, New Delhi, India
| | - S K Verma
- Department of Medical Oncology, Jolly Grant Himalayan Institute, Dehradoon, Uttarakhand, India
| | - P M Parikh
- Department of Oncology, Shalby Cancer and Research Institutes, Mumbai, Maharashtra, India
| | - S Aggarwal
- Department of Medical Oncology, Sir Gangaram Hospital, New Delhi, India
| |
Collapse
|
4
|
Kabra V, Aggarwal R, Vardhan S, Singh M, Khandelwal R, Jain S, Sahani S, Saini S, Deo N, Kaul R, Parikh PM, Aggarwal S. Practical consensus recommendations regarding the management of sentinel lymph node issues in early breast cancer. South Asian J Cancer 2020; 7:132-136. [PMID: 29721480 PMCID: PMC5909291 DOI: 10.4103/sajc.sajc_120_18] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Axillary lymph node involvement is a very important poor prognostic factor in the clinical staging and management of breast cancer patients. Traditionally, axillary lymph node dissection (ALND) has been used for determining the status of the axillary lymph nodes. More recently the sentinel lymph node biopsy (SLNB) procedure has gained wider acceptance as the standard of care, having the advantage of being less invasivewhile providing good accuracy. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations in regards with the use of the two different procedures and other issues in patients with early breast cancer for the benefit of community oncologists.
Collapse
Affiliation(s)
- Vedant Kabra
- Department of Surgical Oncology, Manipal Super Specialty Hospital, New Delhi, India
| | - R Aggarwal
- Department of Surgical Oncology, Medanta Hospital, Gurugram, Haryana, India
| | - S Vardhan
- Department of Surgical Oncology, Mool Chand Hospital, New Delhi, India
| | - M Singh
- Department of Surgical Oncology, Fortis Hospital, New Delhi, India
| | - R Khandelwal
- Department of Surgical Oncology, W Pratiksha Hospital, Gurugram, Haryana, India
| | - S Jain
- Department of Surgical Oncology, DMCH Cancer Care Centre, Ludhiana, Punjab, India
| | - S Sahani
- Department of Surgical Oncology, Indraprastha Apollo Hospital, New Delhi, India
| | - S Saini
- Department of Surgical Oncology, Jolly Grant Himalayan Institute, Dehradun, Uttarakhand, India
| | - N Deo
- Department of Surgical Oncology, Amit Jaggi Memorial Hospital, Agra, Uttar Pradesh, India
| | - R Kaul
- Department of Surgical Oncology, Sir Ganga Ram Hospital, New Delhi, India
| | - P M Parikh
- Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra, India
| | - S Aggarwal
- Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
| |
Collapse
|
5
|
Bhattacharyya GS, Walia M, Nandi M, Murli A, Salim S, Rajpurohit S, Shinde S, Aggarwal S, Parikh PM. Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer. South Asian J Cancer 2020; 7:156-158. [PMID: 29721485 PMCID: PMC5909296 DOI: 10.4103/sajc.sajc_126_18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
This manuscript provides a practical and easy to use consensus recommendation to community oncologists on how to use neoadjuvant chemotherapy in triple negative breast cancer patients.
Collapse
Affiliation(s)
- G S Bhattacharyya
- Department of Medical Oncology, Fortis Hospital, Kolkata, West Bengal, India
| | - M Walia
- Department of Medical Oncology, Max Hospital, New Delhi, India
| | - M Nandi
- Department of Medical Oncology, Jaypee Hospital, Noida, Uttar Pradesh, India
| | - A Murli
- Department of Medical Oncology, Sarvodaya Hospital, Faridabad, Haryana, India
| | - S Salim
- Department of Oncology, Hakim Sanaullah Cancer Center, Sopore, Jammu and Kashmir, India
| | - S Rajpurohit
- Department of Medical Oncology, RGCI, New Delhi, India
| | - S Shinde
- Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
| | - S Aggarwal
- Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
| | - P M Parikh
- Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra, India
| |
Collapse
|
6
|
Sekhon JS, Naik N, Bansal P, Bansal I, Dhull A, Goel A, Ramachandran CS, Shinde S, Aggarwal S, Parikh PM. Practical consensus recommendations for gestational breast cancer. South Asian J Cancer 2020; 7:115-117. [PMID: 29721476 PMCID: PMC5909287 DOI: 10.4103/sajc.sajc_115_18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
This manuscript provides a practical and easy to use consensus recommendation to community oncologists on how to manage gestational breast cancer.
Collapse
Affiliation(s)
- J S Sekhon
- Department of Medical Oncology, Fortis Hospital, Ludhiana, Punjab, India
| | - N Naik
- Department of Surgical Oncology, Dharamshila Cancer Hospital, New Delhi, India
| | - P Bansal
- Department of Medical Oncology, Asian Institute of Medical Sciences, Faridabad, Haryana, India
| | - I Bansal
- Department of Radiation Oncology, Artemis Hospital, Gurugram, Haryana, India
| | - A Dhull
- Department of Radiation Oncology, PGIMS, Rohtak, Haryana, India
| | - A Goel
- Department of Surgical Oncology, Max Hospital, New Delhi, India
| | | | - S Shinde
- Department of Medical Oncology, NCR, New Delhi, India
| | - S Aggarwal
- Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
| | - P M Parikh
- Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra, India
| |
Collapse
|
7
|
Ghadyalpatil NS, Pandey A, Krishnamani I, Srinivas C, Rafiq SJ, Hingmire SS, Maturu N, Reddy R, Kumar KK, Sreekanth K, Gurram BC, Parikh PM. First-line management of metastatic non-small cell lung cancer: An Indian perspective. South Asian J Cancer 2020; 8:73-79. [PMID: 31069181 PMCID: PMC6498710 DOI: 10.4103/sajc.sajc_294_18] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Lung cancer has been the most common cancer in the world for several decades. The non-small cell lung cancer (NSCLC) constitutes approximately about 80% of the total cases of lung cancer. Therapeutic interventions in NSCLC have shifted to the target-based approach from histology-based approach, and this has completely changed the face of the management of NSCLC. Developing countries, such as India, have very limited data compiled about the prevalence and treatment practices of lung cancer, despite a large burden of the disease. However, in recent times, there has been a lot of data generated in this regard. This article is an attempt to collate and shine light on the available data for the first-line treatment of NSCLC in India keeping in mind the current standards of care in this area.
Collapse
Affiliation(s)
| | - Avinash Pandey
- Department of Medical Oncology, IGIMS, Patna, Bihar, India
| | - Iyer Krishnamani
- Department of Medical Oncology, Care Hospital, Hyderabad, Telangana, India
| | - Chilukuri Srinivas
- Department of Radiation Oncology, Apollo Proton Cancer Centre, Chennai, Tamil Nadu, India
| | - Shabnam J Rafiq
- Department of Medical Oncology, Yashoda Hospital, Hyderabad, Telangana, India
| | - Sachin S Hingmire
- Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
| | - Nagarjuna Maturu
- Department of Pulmonology, Yashoda Hospital, Hyderabad, Telangana, India
| | - Ragotham Reddy
- Department of Pulmonology, Yashoda Hospital, Hyderabad, Telangana, India
| | - Kiran K Kumar
- Department of Radiation Oncology, Yashoda Hospital, Hyderabad, Telangana, India
| | - K Sreekanth
- Department of Surgical Oncology, Yashoda Hospital, Hyderabad, Telangana, India
| | | | - P M Parikh
- Department of Medical Oncology, Asian Institute of Oncology, Mumbai, Maharashtra, India
| |
Collapse
|
8
|
Buzzetti E, Parikh PM, Gerussi A, Tsochatzis E. Gender differences in liver disease and the drug-dose gender gap. Pharmacol Res 2017; 120:97-108. [PMID: 28336373 DOI: 10.1016/j.phrs.2017.03.014] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Revised: 03/17/2017] [Accepted: 03/17/2017] [Indexed: 12/14/2022]
Abstract
Although gender-based medicine is a relatively recent concept, it is now emerging as an important field of research, supported by the finding that many diseases manifest differently in men and women and therefore, might require a different treatment. Sex-related differences regarding the epidemiology, progression and treatment strategies of certain liver diseases have long been known, but most of the epidemiological and clinical trials still report results only about one sex, with consequent different rate of response and adverse reactions to treatment between men and women in clinical practice. This review reports the data found in the literature concerning the gender-related differences for the most representative hepatic diseases.
Collapse
Affiliation(s)
- Elena Buzzetti
- UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK.
| | - Pathik M Parikh
- UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK
| | - Alessio Gerussi
- UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK; Internal Medicine Unit, Department of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy
| | - Emmanuel Tsochatzis
- UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK
| |
Collapse
|
9
|
Batra U, Parikh PM, Prabhash K, Tongaonkar HB, Chibber P, Dabkara D, Deshmukh C, Ghadyalpatil N, Hingmire S, Joshi A, Raghunath SK, Rajappa S, Rajendranath R, Rawal SK, Singh M, Singh R, Somashekhar SP, Sood R. Oncology Gold Standard™ practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma. South Asian J Cancer 2016; 5:167-175. [PMID: 28032079 PMCID: PMC5184749 DOI: 10.4103/2278-330x.189933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
The Oncology Gold Standard (OGS) Expert Group on renal cell carcinoma (RCC) developed the consensus statement to provide community oncologists practical guidelines on the management of advanced clear cell (cc) RCC using published evidence, practical experience of experts in real life management, and results of a nationwide survey involving 144 health-care professionals. Six broad question categories containing 33 unique questions cover major situations in the routine management of RCC. This document serves as a ready guide for the standard of care to optimize outcome. The table of "Take Home Messages" at the end is a convenient tool for busy practitioners.
Collapse
Affiliation(s)
| | | | - PM Parikh
- Correspondence to: Dr Purvish M. Parikh, Department of Precision Oncology, Asian Cancer Institute, Somaiya Hospital, Sion East, Mumbai. E-mail:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Parikh PM, Ranade AA, Govind B, Ghadyalpatil N, Singh R, Bharath R, Bhattacharyya GS, Koyande S, Singhal M, Vora A, Verma A, Hingmire S. Lung cancer in India: Current status and promising strategies. South Asian J Cancer 2016; 5:93-5. [PMID: 27606289 PMCID: PMC4991145 DOI: 10.4103/2278-330x.187563] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Affiliation(s)
- P M Parikh
- Asian Cancer Institute, KJ Somaiya Ayurvihar, Mumbai, Maharashtra, India
| | - A A Ranade
- Avinash Cancer Clinic, Pune, Maharashtra, India
| | - Babu Govind
- Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India
| | | | - R Singh
- HCG Cancer Center, New Delhi, India
| | - R Bharath
- Kovai Hospital, Coimbatore, Tamil Nadu, India
| | | | - S Koyande
- Indian Cancer Society, Mumbai, Maharashtra, India
| | - M Singhal
- Indraprastha Apollo Hospital, New Delhi, India
| | - A Vora
- Max Hospital, New Delhi, India
| | - A Verma
- Max Hospital, New Delhi, India
| | - S Hingmire
- Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
| |
Collapse
|
11
|
Affiliation(s)
- P M Parikh
- Department of Precision Oncology, Asian Cancer Institute, Sion East, Mumbai, Maharashtra, India
| | - S S Hingmire
- Department of Oncology, Deenanath Mangeshkar Hospital, Erandwane, Pune, Maharashtra, India
| | - C D Deshmukh
- Department of Oncology, Deenanath Mangeshkar Hospital, Erandwane, Pune, Maharashtra, India
| |
Collapse
|
12
|
Affiliation(s)
- P M Parikh
- Department of Education, BSES Municipal Hospital, Andheri, India
| | | | | | | | | | | | | |
Collapse
|
13
|
Parikh PM, Prabhash K, Govind KB, Digumarti R, Pandit S, Banerjee I, Biyani R, Deshmukh A, Doval D, Bhattacharyya GS, Gupta S. Standard operating procedure for audio visual recording of informed consent: an initiative to facilitate regulatory compliance. Indian J Cancer 2014; 51:113-6. [PMID: 25104190 DOI: 10.4103/0019-509x.138158] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
The office of the Drugs Controller General (India) vide order dated 19 th November 2013 has made audio visual (AV) recording of the informed consent mandatory for the conduct of all clinical trials in India. We therefore developed a standard operating procedure (SOP) to ensure that this is performed in compliance with the regulatory requirements, internationally accepted ethical standards and that the recording is stored as well as archived in an appropriate manner. The SOP was developed keeping in mind all relevant orders, regulations, laws and guidelines and have been made available online. Since, we are faced with unique legal and regulatory requirements that are unprecedented globally, this SOP will allow the AV recording of the informed consent to be performed, archived and retrieved to demonstrate ethical, legal and regulatory compliance. We also compared this to the draft guidelines for AV recording dated 9 th January 2014 developed by Central Drugs Standard Control Organization. Our future efforts will include regular testing, feedback and update of the SOP.
Collapse
Affiliation(s)
- P M Parikh
- SAARC Federation of Oncology, Mumbai, India
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Ranade AA, Joshi DA, Phadke GK, Patil PP, Kasbekar RB, Apte TG, Dasare RR, Mengde SD, Parikh PM, Bhattacharyya GS, Lopes GL. Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India. Ann Oncol 2014; 24 Suppl 5:v6-12. [PMID: 23975704 DOI: 10.1093/annonc/mdt322] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Paclitaxel (Taxol), one of the most commonly used chemotherapeutic agents, is poorly soluble in water and requires cremophor, which often causes infusion reactions, as a solvent. Nanoxel, a nanoparticle formulation of the taxane, has been approved by the Indian regulatory authority. In the present article, we aim to describe the experience with the use of Nanoxel in India and its clinical and economic implications. We present three retrospective series in a common practice environment and an economic model. The first series shows no reactions in 596 Nanoxel infusions; the second series shows comparable adverse events other than infusion reactions between 83 patients who received Nanoxel and 32 treated with conventional paclitaxel. The third reveals comparable clinical outcomes for 51 patients treated with Nanoxel or conventional paclitaxel for gastroesophageal tumors. Finally, we describe an economic model which estimates savings of 21 580 Indian rupees per cycle with Nanoxel vis-à-vis conventional paclitaxel in the treatment of solid tumors in India. In conclusion, in an era in which the greatest challenge we face as medical oncologists is how to conciliate hard-won and incremental--but small--improvements in survival with exponentially rising drugs costs, it is refreshing to see a potential new formulation of a commonly used drug that may actually generate cost-savings while improving clinical outcomes and patient well-being. Further studies are clearly warranted to determine the optimal dose and schedule for Nanoxel as well as its comparative effectiveness to cremophor-based paclitaxel.
Collapse
Affiliation(s)
- A A Ranade
- Department of Medical Oncology, Deenananth Mangeshkar Hospital, Pune, Maharashtra, India
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Parikh PM, Prabhash K, Wenjie J. "Welcome to the China Special Issues of IJC". Indian J Cancer 2014; 51 Suppl 2:e1. [DOI: 10.4103/0019-509x.151982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
16
|
Noronha V, Joshi A, Ghosh J, Parikh PM, Prabhash K. Leptomeningeal metastasis in solid tumors with a special focus on lung cancer. Indian J Cancer 2014; 51:410-3. [DOI: 10.4103/0019-509x.175351] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
17
|
Parikh PM, Gupta S, Dawood S, Rugo H, Bhattacharyya GS, Agarwal A, Chacko R, Sahoo TP, Babu G, Agarwal S, Munshi A, Goswami C, Smruti BK, Bondarde S, Desai C, Rajappa S, Somani N, Singh M, Nimmagadda R, Pavitran K, Mehta A, Parmar V, Desai S, Nair R, Doval D. ICON 2013: Practical consensus recommendations for hormone receptor-positive Her2-negative advanced or metastatic breastcancer. Indian J Cancer 2014; 51:73-9. [DOI: 10.4103/0019-509x.134650] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
18
|
Abstract
The availability of imatinib followed by other tyrosine kinase inhibitors (TKIs) has dramatically altered the outcome of gastrointestinal stromal tumor (GIST). Patients with advanced or poor risk disease can now expect survival measured in years instead of months. An experienced multi disciplinary team (MDT) will be able to personalize therapy to ensure maximum benefit. This review will provide the updated information and finer points regarding state of the art management of GIST with the use of imatinib and other TKIs.
Collapse
Affiliation(s)
- P M Parikh
- Indian Cooperative Oncology Network, 74 Jerbai Wadia Road, Parel East, Mumbai, India
| | | |
Collapse
|
19
|
Jadhav MP, Shinde VM, Chandrakala S, Jijina F, Menon H, Arora B, Kurkure PA, Parikh PM, Kshirsagar NA. A randomized comparative trial evaluating the safety and efficacy of liposomal amphotericin B (Fungisome) versus conventional amphotericin B in the empirical treatment of febrile neutropenia in India. Indian J Cancer 2012; 49:107-13. [PMID: 22842177 DOI: 10.4103/0019-509x.98933] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND In patients with persistent fever and netropenia, amphotericin B is administered empirically for early treatment and prevention of systemic fungal infections. Despite this treatment, there are chances of breakthrough fungal infections and drug is also toxic. MATERIALS AND METHODS A multicentric, randomized, controlled clinical trial was conducted to compare liposomal amphotericin B two doses with conventional amphotericin B as empirical antifungal therapy. RESULTS The average body weight of patients was 26.4 ± 14.8 (n=22), 32.9 ± 19.4 (n=23) and 37.9 ± 20.0 (n=20) kg in 1 mg, 3 mg Fungisome (liposomal amphotericin B) and 1 mg/kg/day conventional amphotericin B group, respectively. The mean age was 16.2 ± 13.4, 16.0 ± 10.9 and 22.7 ± 16.2 yrs in 1 and 3 mg/kg/day Fungisome and 1 mg/kg/day conventional AMP B group, respectively. The average duration of treatment with 1 mg and 3 mg/kg/day Fungisome and 1 mg/kg/day conventional amphotericin B was 17 ± 9.8, 16.2 ± 8.3, and 14.7 ± 10.7 days, respectively. The time to resolve fever was 13.3 ± 10.2, 10.9 ± 7.1, 10.1 ± 6.7 days, and for absolute neutrophil count (ANC) to be above 500 cells per microliter, it took 13.4 ± 9.6, 10.6 ± 7.6 and 7.3 ± 3.4 days, respectively. Liposomal formulations were well-tolerated compared to conventional amphotericin B. CONCLUSIONS This small randomized study showed that the indigenous liposomal formulation Fungisome appears to be equally efficacious and safer than conventional amphotericin B. Also, the lower dose Fungisome (1 mg/kg/day) appears to be equally efficacious and was well-tolerated as compared to higher dose Fungisome (3 mg/kg/day). Treatment cost would be a major factor for limiting use of higher dose of Fungisome.
Collapse
Affiliation(s)
- M P Jadhav
- Department of Clinical Pharmacology, Seth G.S. Medical College and KEM Hospital, Mumbai, India
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Parikh PM, Gupta S, Parikh B, Smruti BK, Issrani J, Topiwala S, Goswami C, Bhattacharya GS, Sen T, Sekhon JS, Malhotra H, Nag S, Chacko RT, Govind KB, Raja T, Vaid AK, Doval DC, Gupta S, Das PK. Management of primary and metastatic triple negative breast cancer: perceptions of oncologists from India. Indian J Cancer 2011; 48:158-64. [PMID: 21768659 DOI: 10.4103/0019-509x.82874] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND In order to document the understanding of current evidence for the management of triple negative breast cancer and application of this knowledge in daily practice, we conducted an interactive survey of practicing Indian oncologists. MATERIALS AND METHODS A core group of academic oncologists devised two hypothetical triple negative cases (metastatic and early breast cancer, respectively) and multiple choice options under different clinical circumstances. The respondents were practicing oncologists in different Indian cities who participated in either an online survey or a meeting. The participants electronically chose their preferred option based on their everyday practice. RESULTS A total of 152 oncologists participated. Just over half (53.8%) preferred taxane based chemotherapy as first-line chemotherapy in the metastatic setting. In the adjuvant setting, a taxane regimen was chosen by 61%. Over half of respondents (52.6%) underestimated the baseline survival of a patient with node positive triple-negative tumor and 18.9% overestimated this survival compared to the estimate of the Adjuvant! program. DISCUSSION This data offers insight into the perceptions and practice of a diverse cross-section of practicing oncologists in India with respect to their therapeutic choices in metastatic and adjuvant settings in triple negative breast cancer.
Collapse
Affiliation(s)
- P M Parikh
- Indian Co-operative Oncology Network, Mumbai, India.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
Glioblastoma is a rapidly progressive and extremely fatal form of brain tumor with poor prognosis. It is the most common type of primary brain tumor. Even with the most aggressive conventional treatment that comprises surgery followed by radiotherapy and chemotherapy, most patients die within a year of diagnosis. Developments in molecular and cell biology have led to better understanding of tumor development, leading to novel treatment strategies including biological therapy and immunotherapy to combat the deadly disease. Targeted drug delivery strategies to circumvent the blood-brain barrier have shown efficiency in clinical trials. Gliadel wafer is a new approach to the treatment of glioblastoma, which involves controlled release delivery of carmustine from biodegradable polymer wafers. It has shown promising results and provides a silver lining for glioblastoma patients.
Collapse
Affiliation(s)
- M Panigrahi
- Department of Neurosurgery, Krishna Institute of Medical Sciences, Secunderabad, India
| | | | | |
Collapse
|
22
|
|
23
|
Abstract
This review article provides the current recommendations and evidence for the correct management of anemia in cancer patients. The various options available include transfusions, iron and erythropoiesis stimulation. The indications, pros and cons of each option are discussed.
Collapse
Affiliation(s)
- K Prabhash
- Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
| | | | | | | |
Collapse
|
24
|
|
25
|
Bharath R, Parikh PM. Breast cancer: search for new targets and improvement of existing techniques. Indian J Cancer 2010; 47:95-7. [PMID: 20448369 DOI: 10.4103/0019-509x.62993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
26
|
Jain P, Prabhash K, Menon H, Gupta S, Parikh PM. Lymphoma masquerading as acute leukemia-mystery unfolded. Indian J Cancer 2010; 47:222-3. [PMID: 20448392 DOI: 10.4103/0019-509x.63001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
|
28
|
|
29
|
Gujral S, Badrinath Y, Kumar A, Subramanian PG, Raje G, Jain H, Pais A, Amre Kadam PS, Banavali SD, Arora B, Kumar P, Hari Menon VG, Kurkure PA, Parikh PM, Mahadik S, Chogule AB, Shinde SC, Nair CN. Immunophenotypic profile of acute leukemia: critical analysis and insights gained at a tertiary care center in India. Cytometry B Clin Cytom 2009; 76:199-205. [PMID: 18803279 DOI: 10.1002/cyto.b.20451] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND To analyze the spectrum of various types and subtypes of acute leukemia. METHODS Two thousand five hundred and eleven consecutive new referral cases of acute leukemia (AL) were evaluated based on WHO classification. RESULTS It included 1,471 cases (58%) of acute lymphoblastic leukemia (ALL), 964 cases (38%) of acute myeloid leukemia (AML), 45 cases (1.8%) of chronic myelogenous leukemia in blast crisis (CMLBC), 37 cases (1.5%) of biphenotypic acute leukemia (BAL), 1 case of Triphenotypic AL, and 2 cases of acute undifferentiated leukemia (AUL). Common subtypes of ALL were B-cell ALL (76%), which comprised of intermediate stage/CALLA positive (73%), early precursor/proBALL (3%). T-cell ALL constituted 24% (351 cases) of ALL. Common subtypes of AML included AMLM2 (27%), AMLM5 (15%), AMLM0 (12%), AMLM1 (12%), APML (11%), and AML t(8;21) (9%). CMLBC was commonly of myeloid blast crisis subtype (40 cases). CONCLUSION B-cell ALL was the commonest subtype in children and AML in adults. Overall incidence of AML in adults was low (53% only). CD13 was most sensitive and CD117 most specific for determining myeloid lineage. A minimal primary panel of nine antibodies consisting of three myeloid markers (CD13, CD33, and CD117), B-cell lymphoid marker (CD19), T-cell marker (CD7), with CD45, CD10, CD34, and HLADR could assign lineage to 92% of AL. Cytogenetics findings lead to a change in the diagnostic subtype of myeloid malignancy in 38 (1.5%) cases.
Collapse
Affiliation(s)
- S Gujral
- Department of Pathology, Tata Memorial Hospital, Mumbai, India.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
|
31
|
Prabhash K, Vikram GS, Nair R, Sengar M, Gujral S, Bakshi A, Gupta S, Parikh PM. Fludarabine in lymphoproliferative malignancies: a single-centre experience. Natl Med J India 2008; 21:171-174. [PMID: 19267037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
BACKGROUND Fludarabine has been reported to be an effective drug for the treatment of chronic lymphocytic leukaemia (CLL) and indolent lymphomas. However, its safety and efficacy in Indian patients has not been studied. We retrospectively analysed our experience with fludarabine in low grade lymphomas and CLL. METHODS The records of all patients with low grade lymphoma or CLL who received fludarabine between April 1999 and November 2006 were analysed. Response evaluation was done as per the National Cancer Institute-Working Group guidelines for CLL and International Workshop criteria for non-Hodgkin lymphomas, respectively, in those patients who received at least 3 cycles of fludarabine. Toxicity was graded as per the common terminology criteria for adverse events, version 3.0. Median event-free survival was obtained using Kaplan-Meier survival analysis. RESULTS Forty-seven patients were included in the study and 189 cycles were administered (median: 4 cycles per patient). Sixteen patients had a treatment delay, 14 due to myelosuppression. Twenty-five patients had low grade lymphoma and 22 had CLL. The response was evaluable in 22 patients with low grade lymphoma and 20 with CLL. The overall response rate for CLL was 100% in those treated upfront (n=9) and 55% in those with relapsed disease (n=11). The overall response rate for low grade lymphoma was 88% (63% complete remission) in untreated patients and 79% (43% complete remission) in those with relapsed disease. Common adverse events were myelosuppression and infection. Two patients died of sepsis and 4 due to disease progression on treatment. Median event-free survival for patients treated upfront with fludarabine was 31.4 months. CONCLUSION In our patient population, response to fludarabine is similar to that in the published literature. Our patients had a higher frequency of haematological toxicity.
Collapse
Affiliation(s)
- K Prabhash
- Department of Medical Oncology, Tata Memorial Hospital, Dr Ernest Borges Marg, Parel, Mumbai 400012, Maharashtra, India
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Hingmire SS, Biswas G, Bakshi A, Desai S, Dighe S, Nair R, Gupta S, Parikh PM. Cytomegalovirus oesophagitis in a patient with Non-Hodgkin's lymphoma. Indian J Med Microbiol 2008; 26:79-80. [PMID: 18227606 DOI: 10.4103/0255-0857.38866] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Cytomegalovirus (CMV) infection is frequent in immunocompromised patients, especially in AIDS, organ transplantation and rarely in Hodgkin's disease and Non-Hodgkin's lymphoma (NHL). We present a case of NHL with CMV oesophagitis, which has rarely been documented in literature. Apart from fungal and herpes simplex infections, as the common differential diagnosis for oesophagitis in patients of lymphoma, CMV should be considered an important etiologic agent. Early diagnosis and prompt treatment of CMV oesophagitis with gancyclovir can avert significant morbidity and avoid unacceptable treatment delays.
Collapse
Affiliation(s)
- S S Hingmire
- Department of Medical Oncology, Tata Memorial Hospital, Mumbai - 400 012, Maharashtra, India.
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Parikh PM, Bhattacharyya GS. Dynamic long distance management of patient variables: application in ameliorating chemotherapy-associated side effects. Indian J Cancer 2008; 45:1-3. [PMID: 18453732 DOI: 10.4103/0019-509x.40638] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
34
|
Abstract
BACKGROUND In 2004, the authors reported their findings with placement of tissue expanders for breast reconstruction in the partial submuscular position, the equivalent of the "dual-plane" technique for breast augmentation. Limitations with subpectoral expander placement include difficulty controlling the lower pole of the pocket during expansion, unprotected device coverage by a thin inferior mastectomy flap, possible effacement of the inframammary fold, and limited control over the superior migration of the pectoralis major muscle. This study aimed to examine the safety and efficacy of an acellular dermal sling in providing inferolateral support to the device during immediate breast reconstruction and expansion. METHODS This study prospectively investigated 58 breasts of 43 consecutive women who underwent immediate breast reconstruction with tissue expanders and acellular dermis. After completion of adjuvant therapy and expansion, the devices were exchanged for implants. The patients were tracked through January, 2007. The study parameters included demographic information, oncologic data, complications, and aesthetic outcomes. RESULTS The mean time required to complete reconstruction was 8.6 months. The overall complication rate after expander/acellular dermis placement was 12%, whereas the complication rate after exchange to implants was 2.2%. The aesthetic outcome for reconstructed breasts did not differ significantly from that for the control subjects who had no surgery. CONCLUSIONS Acellular dermis appears to be a useful adjunct in immediate prosthetic breast reconstruction. Acellular dermis-assisted breast reconstruction has a low complication rate, helps to reconstruct an aesthetically pleasing breast, and facilitates expeditious completion of the reconstruction.
Collapse
Affiliation(s)
- S L Spear
- Department of Plastic Surgery, Georgetown University, 1st Floor PHC Building, 3800 Reservoir Road NW, Washington, DC 20007, USA
| | | | | | | |
Collapse
|
35
|
Jain S, Agarwal JP, Gupta T, Parikh PM, Mistry RC, Menon H, Pramesh CS, Shrivastava SK. Case report: Second primary small cell carcinoma of the trachea in a breast cancer survivor: a case report and literature review. Br J Radiol 2008; 81:e120-2. [PMID: 18344270 DOI: 10.1259/bjr/97077007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Small cell carcinoma of the trachea is a rare entity and only a few cases have been described, none as a second malignant neoplasm. This is the first report of a metachronous second primary of the trachea with small cell histology in a breast cancer survivor. A 25-year-old woman was diagnosed initially with an infiltrating ductal carcinoma of the breast, and was treated with modified radical mastectomy followed by adjuvant chemo-radiotherapy. 10 years later, she presented with breathlessness and central airway obstruction. Bronchoscopy revealed an intraluminal lesion in the proximal trachea, which was reported as small cell carcinoma on biopsy. There was no evidence of loco-regional recurrence of the previously treated breast cancer. Whole-body positron emission tomography did not show any distant metastases. As it was a small cell carcinoma, she was treated with concurrent chemo-radiotherapy and remains loco-regionally controlled. Decision-making in such instances should take into account prior treatment and needs to be individualized. There is a need for increased awareness amongst primary care physicians regarding second malignant neoplasms in the long-term follow-up of breast cancer patients treated with radiation and chemotherapeutic agents that have carcinogenic potential.
Collapse
Affiliation(s)
- S Jain
- Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mambai, India
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Hingmire SS, Biswas G, Bakshi A, Desai S, Dighe S, Nair, Gupta S, Parikh PM. CYTOMEGALOVIRUS OESOPHAGITIS IN A PATIENT WITH NON-HODGKIN’S LYMPHOMA. Indian J Med Microbiol 2008. [DOI: 10.1016/s0255-0857(21)02000-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
37
|
|
38
|
Abstract
Advances in cancer management have resulted in a significant increase in median survival of number of diseases. Consequently we are seeing more patients living long enough to develop symptomatic brain metastases. The management of such patients will be discussed here. The most important definitive investigation is contrast enhanced MRI scan of brain. Management consists of supportive care and disease directed treatment. Surgical resection remains the gold standard for the treatment of solitary brain metastases. Whole brain radiotherapy is considered standard treatment for all patients with brain metastases. The role of chemotherapy was limited in the past. Recently several new agents have been identified as potentially useful. Preliminary results indicate that drugs like temozolomide and topotecan have antitumor activity against the brain metastases as well as the primary systemic malignancies. The goal of multimodality treatment for brain metastases is to palliate local symptoms and prevent consequences of neurological involvement.
Collapse
Affiliation(s)
- G Biswas
- Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai-400 012, India
| | | | | | | | | | | |
Collapse
|
39
|
Pranjali K, Prabhash K, Karanth VN, Kane S, Nair R, Parikh PM. Umbilical metastasis: an unusual presentation of pancreatic adenocarcinoma. Indian J Dermatol Venereol Leprol 2007; 73:199-200. [PMID: 17558060 DOI: 10.4103/0378-6323.32751] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Hingmire S, Narayanan P, Khadwal A, Maru D, Biswas G, Sastry PSRK, Parikh PM. Isolated cutaneous relapse of acute myeloid leukemia. J Assoc Physicians India 2007; 55:131. [PMID: 17571743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Affiliation(s)
- S Hingmire
- Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai 400 012
| | | | | | | | | | | | | |
Collapse
|
41
|
Kurkure PA, Parikh PM, Narula G, Bhagwat R, Arora B, Banavali SD, Pai SK, Nair CN, Seth T, Laskar S, Muckaden MA. Clinico-biologic profile of Langerhans cell histiocytosis: A single institutional study. Indian J Cancer 2007; 44:93-8. [DOI: 10.4103/0019-509x.38939] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
42
|
Pathak KA, Juvekar AS, Radhakrishnan DK, Deshpande MS, Pai VR, Chaturvedi P, Pai PS, Chaukar DA, D'Cruz AK, Parikh PM. In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy. Indian J Cancer 2007; 44:142-6. [DOI: 10.4103/0019-509x.39376] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Kurkure PA, Parikh PM, Biswas G, Khadwal A, Arora B, Bhagwat R, Banavali SD, Nair CN, Pai SK. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: A single institutional experience. Indian J Cancer 2007; 44:137-41. [DOI: 10.4103/0019-509x.39375] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
44
|
Prabhash K, Prasad N, Biswas G, Bakshi A, Parikh PM. Hepatocellular carcinoma presenting as double head. Indian J Gastroenterol 2006; 25:255. [PMID: 17090845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Kumar Prabhash
- Department of Medical Oncology, Tata Memorial Hospital, Mumbai 400 012, India
| | | | | | | | | |
Collapse
|
45
|
Prabhash K, Biswas G, Nair R, Pandey D, Maru D, Mahajan A, Parikh PM. Metachronous gastric diffuse large B-cell lymphoma and adenocarcinoma. Indian J Gastroenterol 2006; 25:261-2. [PMID: 17090851 DOI: pmid/17090851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The development of gastric carcinoma in a patient with gastric lymphoma is rare. Helicobacter pylori is a common etiologic agent for both these conditions. We report a 38-year-old lady who was initially diagnosed to have gastric lymphoma and developed early gastric carcinoma on follow up. She was operated on for the carcinoma and is in complete remission since.
Collapse
Affiliation(s)
- Kumar Prabhash
- Department of Medical Oncology, Tata Memorial Hospital, Mumbai 400 012, India.
| | | | | | | | | | | | | |
Collapse
|
46
|
Prabhash K, Biswas G, Prasad N, Karant N, Sastry PSRK, Parikh PM. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Indian J Dermatol Venereol Leprol 2006; 72:63-4. [PMID: 16481719 DOI: 10.4103/0378-6323.19727] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
47
|
Bakshi A, Biswas G, Deshmukh C, Prasad N, Nair R, Parikh PM. Successful complete regression of isolated intramedullary spinal cord metastases from epithelial ovarian carcinoma with chemotherapy and radiotherapy. Indian J Cancer 2006; 43:136-8. [PMID: 17065773 DOI: 10.4103/0019-509x.27937] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Advances in the management of ovarian cancer by use of aggressive surgery and effective platinum-based chemotherapy have prolonged survival; this may have resulted in an alteration of the metastatic pattern of the disease and spread to unusual sites (e.g, CNS) has become more common. Also, with the availability of more sensitive imaging techniques, these tumors are being diagnosed with increasing frequency. Intramedullary spinal cord metastasis is rare. We report one such case treated successfully with chemotherapy and radiotherapy with long-term survival.
Collapse
Affiliation(s)
- A Bakshi
- Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India
| | | | | | | | | | | |
Collapse
|
48
|
|
49
|
Biswas G, Parikh PM, Nair R, Bhagwat R, Bakshi A, Prabhash K, Vora A, Gupta S, Pai VR, Menon H, Sastry PSRK. Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience. J Assoc Physicians India 2006; 54:29-33. [PMID: 16649735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Rituximab has been used extensively in lymphoproliferative disorders. We evaluated the results of 64 consecutive patients treated between 2001 and 2004 at our institution. This included 54 males and 10 females. The median age was 54 years (range 17 to 85 years). One-fourth of patients were above 60 years. The histology was aggressive NHL in 35, indolent NHL in 22 and 7 cases were diagnosed as CLL. Among NHL, sixteen were in early stage (I/II) and the remaining forty-one were in advanced stage (III/IV) of disease. B symptoms were present in 47% of cases. A total of 33 were de novo cases and 31 were previously treated. Rituximab monotherapy was used in 17 cases. Rituximab was used in combination with chemotherapy in the other 47 cases. Infusional toxicity included anaphylaxis in one, hypotension in one and minor infusional reactions in four others. The patient who developed anaphylaxis required discontinuation of further Rituximab. Growth factors were used in 25 patients. Febrile neutropenia occurred in 19 patients. The overall RR (CR + PR) was 72%. One patient had stable disease and progressive disease was documented in 17 patients. A total of seven patients died, three due to progressive disease, three due to chemotherapy related toxicity and one due to an unrelated cause. We conclude that Rituximab is a valuable addition to the treatment armamentarium of lymphoproliferative disorders.
Collapse
Affiliation(s)
- G Biswas
- Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Khadwal A, Prasad N, Biswas G, Bhagwat R, Sastry PSRK, Parikh PM. Spontaneous migration of central venous catheter tip. J Assoc Physicians India 2006; 54:35. [PMID: 16649737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Affiliation(s)
- A Khadwal
- Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India
| | | | | | | | | | | |
Collapse
|